OncoSec Medical to Present at the 25th Annual Roth Conference
SAN DIEGO, March 14, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the 25th Annual Roth Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, California, on Tuesday, March 19th at 8:00AM Pacific Time.
Mr. Dhillon will provide an overview of the Company and its milestones during the presentation, and will be conducting one-on-one meetings with investors who are registered to attend the conference.
The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/roth27/oncs/. The webcast will be archived for 90 days.
About the Annual Roth Conference
The 25th Annual Roth Conference is designed to provide investors with a unique opportunity to gain insight into emerging growth companies across a variety of sectors, including Business Services, Consumer, Cleantech, Industrials & Resources, Healthcare, Metals & Mining and Technology & Media.
The event is one of the largest of its kind in the U.S. It will feature presentations from hundreds of growth companies, expert panels and thousands of management one-on-one/small group meetings. To find out more, visit www.roth.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Inc.